Drug Approval | May 29, 2024
Strides receives USFDA approval for Sucralfate oral suspension, 1gm/10 mL
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Further strengthens BaseLaunch's global pharma industry partnerships
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Subscribe To Our Newsletter & Stay Updated
